Debjit Chattopadhyay
Stock Analyst at Guggenheim
(2.34)
# 2,336
Out of 4,829 analysts
89
Total ratings
44.3%
Success rate
-2.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Buy | $55 → $45 | $8.64 | +420.83% | 2 | May 12, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $81 → $97 | $77.73 | +24.79% | 3 | May 8, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $195 → $189 | $137.11 | +37.85% | 4 | May 7, 2025 | |
| BEAM Beam Therapeutics | Maintains: Buy | $78 → $55 | $18.01 | +205.39% | 3 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $112 → $98 | $38.23 | +156.34% | 5 | May 7, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $65 → $64 | $32.80 | +95.12% | 5 | May 1, 2025 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $19 | $9.98 | +90.38% | 2 | Apr 2, 2025 | |
| CNTA Centessa Pharmaceuticals | Reiterates: Buy | $28 | $12.68 | +120.82% | 6 | Mar 26, 2025 | |
| RZLT Rezolute | Reiterates: Buy | n/a | $3.66 | - | 2 | Feb 10, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | n/a | $12.47 | - | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $12.77 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.35 | +1,238.29% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $13.90 | +22.30% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.19 | +142.52% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $558 | $433.56 | +28.70% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $37.17 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.26 | +261.54% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.29 | +568.69% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $19.03 | +57.65% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $60.97 | +80.42% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.22 | +2,277.05% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.31 | +3,483.06% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $50 | $36.35 | +37.57% | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $259.02 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.15 | +1,202.33% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $6.72 | +197.62% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $25.26 | +386.94% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $11.58 | +366.32% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.40 | +4,185.71% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.51 | - | 3 | Jun 26, 2017 |
Intellia Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $8.64
Upside: +420.83%
Soleno Therapeutics
May 8, 2025
Maintains: Buy
Price Target: $81 → $97
Current: $77.73
Upside: +24.79%
Krystal Biotech
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $137.11
Upside: +37.85%
Beam Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $18.01
Upside: +205.39%
Sarepta Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $112 → $98
Current: $38.23
Upside: +156.34%
Ionis Pharmaceuticals
May 1, 2025
Maintains: Buy
Price Target: $65 → $64
Current: $32.80
Upside: +95.12%
Maze Therapeutics
Apr 2, 2025
Reiterates: Buy
Price Target: $19
Current: $9.98
Upside: +90.38%
Centessa Pharmaceuticals
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $12.68
Upside: +120.82%
Rezolute
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $3.66
Upside: -
Dyne Therapeutics
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $12.47
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $12.77
Upside: -
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $1.35
Upside: +1,238.29%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $13.90
Upside: +22.30%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.19
Upside: +142.52%
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $433.56
Upside: +28.70%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $37.17
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $5.26
Upside: +261.54%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.29
Upside: +568.69%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $19.03
Upside: +57.65%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $60.97
Upside: +80.42%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.22
Upside: +2,277.05%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.31
Upside: +3,483.06%
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $36.35
Upside: +37.57%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $259.02
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $2.15
Upside: +1,202.33%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $6.72
Upside: +197.62%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $25.26
Upside: +386.94%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $11.58
Upside: +366.32%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.40
Upside: +4,185.71%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $28.51
Upside: -